CTNNB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL168979	0.57	10/20
Quercetin-3'-O-Phosphate (SCHEMBL118113)	0.67	9/20
SCHEMBL117682	0.65	9/20
SCHEMBL29019	0.47	9/20
SCHEMBL175424	0.64	8/20
SCHEMBL103953	0.59	8/20
SCHEMBL170340	0.59	8/20
Gossypetin (SCHEMBL157033)	0.73	7/20
Hydrochloric Acid (SCHEMBL72907)	0.49	7/20
SCHEMBL8447	0.46	7/20
SCHEMBL29063	0.42	7/20
SCHEMBL220455	0.65	6/20
SCHEMBL261380	0.65	6/20
SCHEMBL122504	0.61	6/20
SCHEMBL145658	0.60	6/20
SCHEMBL151368	0.56	6/20
SCHEMBL264383	0.51	6/20
SCHEMBL264384	0.51	6/20
SCHEMBL171665	0.48	6/20
SCHEMBL241094	0.48	6/20

Clinical trials — most relevant to CTNNB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer	PHASE2	UNKNOWN
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy	PHASE2	RECRUITING
Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel	PHASE2	NOT_YET_RECRUITING
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome	PHASE1/PHASE2	RECRUITING
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor	PHASE1/PHASE2	COMPLETED
Mesalazine Effects in Sporadic Colorectal Adenoma Patients	PHASE2	COMPLETED
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors	PHASE1	RECRUITING
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma	PHASE1	RECRUITING
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study	nan	COMPLETED
Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients	nan	COMPLETED
CTNNB1 Neurodevelopmental Syndrome - Natural History Study	nan	RECRUITING
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.	nan	RECRUITING
Genotype-phenotype Correlations in Children and Adults With CTNNB1 Mutation	nan	COMPLETED
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer	nan	COMPLETED
Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation	nan	RECRUITING
Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53	nan	UNKNOWN
CTNNA1 Familial Expansion Study	nan	RECRUITING
LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION	nan	RECRUITING
B-catenin in Cutaneous Squamous Cell Carcinoma and Its Mimickers	nan	RECRUITING
Klotho _ LRP-6 _ Gastric Adenocarcinoma	nan	UNKNOWN
Profiling Gingival Crevicular Fluid β-Catenin Level With 8-OHdG and Total Antioxidants Capacity During Healing of Periodontal Pockets: A 3-month Clinical Trial	nan	NOT_YET_RECRUITING
Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins	nan	COMPLETED
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment	nan	COMPLETED
Effect of Non-Surgical Periodontal Therapy on Salivary Biomarkers in Smokers and Non-Smokers With Periodontitis	nan	RECRUITING
Precision-Based Genomics in Prostate Cancer	nan	RECRUITING
Liquid Biopsies for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CTNNB1 binder may also engage these)

Protein	Name	Similarity
B6V8E6	—	1.000	B6V8E6 →
Q0VCX4	—	1.000	Q0VCX4 →
Q02248	—	1.000	Q02248 →
Q9WU82	—	1.000	Q9WU82 →
F1QGH7	—	1.000	F1QGH7 →
P26233	—	1.000	P26233 →
Q92845	—	0.975	Q92845 →
P70188	—	0.966	P70188 →
P35224	—	0.961	P35224 →
STAT5B	Signal transducer and activator of transcription 5B	0.953	landscape →
Q9Y3P9	—	0.952	Q9Y3P9 →
Q9TUZ0	—	0.952	Q9TUZ0 →
Q8K4Q0	—	0.952	Q8K4Q0 →
Q5RAN1	—	0.951	Q5RAN1 →
Q9TUM3	—	0.951	Q9TUM3 →
RPTOR	Regulatory-associated protein of mTOR	0.951	landscape →
B4ZIX8	—	0.951	B4ZIX8 →
P42232	—	0.951	P42232 →
Q62771	—	0.951	Q62771 →
P50904	—	0.950	P50904 →
P52632	—	0.950	P52632 →
A4IIX9	—	0.950	A4IIX9 →
Q9TUZ1	—	0.949	Q9TUZ1 →
Q6GQW0	—	0.947	Q6GQW0 →
Q95115	—	0.947	Q95115 →
STAT5A	Signal transducer and activator of transcription 5A	0.947	landscape →
AP2A2	AP-2 complex subunit alpha-2	0.946	landscape →
P20936	—	0.946	P20936 →
Q4I1B1	—	0.946	Q4I1B1 →
O88506	—	0.945	O88506 →